In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Questcor Pharmaceuticals Inc.

Division of Mallinckrodt PLC
www.questcor.com

Latest From Questcor Pharmaceuticals Inc.

Mallinckrodt Settles Portion Of DOJ's Acthar Gel Kickback Claims; Charity Copay Probe Continues

$15.4m fine will resolve claims of "wining and dining" doctors to get them to prescribe Acthar. Mallinckrodt dropped NORD and switched to Chronic Disease Fund to administer its copay assistance program, a move that Mallinckrodt’s COO purportedly described as "mom & pop vs. WalMart."

Enforcement Legal Issues

Biopharma Quarterly Deal-making Statistics, Q4 2017

Biopharma financing finished off 2017 strong with a total value of $14.5 billion in Q4, led again by FOPOs. CVS' massive $77 billion acquisition of Aetna resulted in an all-time quarterly high in the M&A category, and the largest alliances were dominated by the development of vaccines and antibodies.

Deals Market Intelligence

Payer Pushback Underpins Mallinckrodt's Disappointing Q3 Results

Mallinckrodt's high-priced H.P Acthar Gel was under pressure in the third quarter, which management attributed to payer complexities. The issue is broader than just Acthar, firm says.

Sales & Earnings Reimbursement

Finance Watch: Rhythm And OptiNose IPOs Bring 2017 Total To 31, Surpassing 2016

Public Company Financings: Rhythm and OptiNose are the 30th and 31st initial public offerings of 2017. Also, reverse mergers add two more newly public firms, Valeant raises $1bn to pay down more debt, and PhaseRx and Trevena cut jobs.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Inflammation
  • Neurology, Nervous System
  • Alias(es)
  • RiboGene Inc.
  • Cypros Pharmaceutical Corp.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Mallinckrodt PLC
  • Senior Management
  • Don M Bailey, Pres. & CEO
    David Young, PhD, CSO
    Dave Medeiros , EVP, CTO
    Michael Aldridge, SVP, Corp. Strategic Dev.
  • Contact Info
  • Questcor Pharmaceuticals Inc.
    Phone: (714) 786-4200
    1300 North Kellogg Dr.
    Suite D
    Anaheim Hills, CA 92807
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register